Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,68
KB-0,29
PKN67,0767,13-0,71
Msft-1,84
Nokia3,11053,2692,05
IBM-0,89
Mercedes-Benz Group AG75,0675,080,55
PFE-0,12
18.04.2024 22:30:00
Indexy online
AD Index online
select
AD Index online
 

  • 18.04.2024 17:17:32
Futura Medical (FUM.L, London)
Poslední obchod Změna (%) Změna (GBP) Objem obchodů (GBP)
0,354 -3,01 -0,01 31 091
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 18.04.2024
Popis společnosti
Obecné informace
Název společnostiFutura Medical PLC
TickerFUM
Kmenové akcie:Ordinary Shares
RICFUM.L
ISINGB0033278473
Poslední známé roční výsledky31.12.2022
Poslední známé čtvrtletní výsledky30.06.2023
Počet zaměstnanců k 31.12.2022 12
Akcie v oběhu k 22.01.2024 301 449 451
MěnaGBP
Kontaktní informace
Ulice40 Occam Road
MěstoGUILDFORD
PSČGU2 7YG
ZeměUnited Kingdom
Kontatní osobaJames Barder
Funkce kontaktní osobyGroup Chief Executive, Executive Director
Telefon441 483 685 670
Fax441483685671
Kontatní telefon441 483 685 670

Business Summary: Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Futura Medical PLC revenues increased from L0K to L1.7M. Net loss decreased 30% to L1.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development costs decrease of 57% to L819K (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -L0.01.
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 18.04.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Group Chief Executive, Executive DirectorJames Barder59
Finance Director, Chief Operating Officer, Company Secretary, Executive DirectorAngela Hildreth-
Executive Director, Head of R&DKen James6716.11.201616.11.2016